Posted On: 01/05/2015 9:36:34 AM
Post# of 94182
$OXGN Recent News
Herbalife tumbles on FTC probe; Plug Power rebounds 3:30 p.m. March 12, 2014 - Sue Chang
Oxigene shares more than double on ovarian cancer treatment results 9:58 a.m. March 12, 2014 - Russ Britt
Stock futures pulled lower by China, Ukraine worries 8:23 a.m. March 12, 2014 - William L. Watts
Plug plunges, Ukraine pops and how Twitter traded the bull market 8:09 a.m. March 12, 2014 - Shawn Langlois
Oxigene shares surge after positive clinical trial 7:39 a.m. March 12, 2014 - Saumya Vaishampayan
VeriFone shares surge after earnings, outlook 4:22 p.m. March 11, 2014 - Wallace Witkowski
Oxigene soars on ovarian cancer drug results 4:05 p.m. March 11, 2014 - MarketWatch.com
Oxigene shares jump 122% to $5.37 on study result 4:00 p.m. March 11, 2014 - Wallace Witkowski
Monday’s biggest gaining and declining stocks 5:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 2:42 p.m. June 6, 2011 - Val Brickates Kennedy
Oxigene soars on Nasdaq update 8:46 a.m. June 6, 2011 - Val Brickates Kennedy
U.S. stock futures drift; Apple’s Jobs ahead 8:04 a.m. June 6, 2011 - Kate Gibson
Diet-drug makers grab sector spotlight 2:53 p.m. June 3, 2011 - Val Brickates Kennedy
Oxigene rallies 30% ahead of study presentations 11:39 a.m. June 3, 2011 - Val Brickates Kennedy
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against? 11:42 a.m. Nov. 17, 2014 - Seeking Alpha
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated 4:20 p.m. Nov. 14, 2014 - Seeking Alpha
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy 9:15 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: OXIGENE INC 10:30 a.m. Nov. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript 9:27 p.m. Nov. 12, 2014 - Seeking Alpha
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast 4:25 p.m. Nov. 12, 2014 - Seeking Alpha
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data 5:12 a.m. Nov. 12, 2014 - TheStreet.com
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact 5:56 a.m. Nov. 11, 2014 - Seeking Alpha
OxiGene presents Phase 2 data on fosbretabulin 12:31 p.m. Nov. 10, 2014 - Seeking Alpha
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting 10:15 a.m. Nov. 6, 2014 - Seeking Alpha
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta 7:28 a.m. Oct. 24, 2014 - TheStreet.com
Update: OXiGENE Initiates Clinical Trial -- Shares Rise 6:35 a.m. Sept. 18, 2014 - Seeking Alpha
Update: OXiGENE Earnings - Q2 Miss Challenges My Patience 11:48 a.m. Aug. 6, 2014 - Seeking Alpha
OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 Results - Earnings Call Transcript 7:29 p.m. Aug. 5, 2014 - Seeking Alpha
OXiGENE (OXGN) Q2 2014 Results - Earnings Call Webcast 3:25 p.m. Aug. 5, 2014 - Seeking Alpha
Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis 2:00 p.m. July 28, 2014 - Seeking Alpha
10-Q: OXIGENE INC 2:44 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE's (OXGN) CEO Peter Langecker on Q1 2014 Results - Earnings Call Transcript 7:21 p.m. May 6, 2014 - Seeking Alpha
Q1 2014 O Xi Gene, Inc Earnings Conference Call (OXGN) Q1 2014 Results - Earnings Call Webcast 3:25 p.m. May 6, 2014 - Seeking Alpha
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting 8:01 a.m. Nov. 20, 2014 - GlobeNewswire
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies 4:01 p.m. Nov. 17, 2014 - GlobeNewswire
OXiGENE Reports Third Quarter 2014 Financial Results 4:04 p.m. Nov. 12, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer 3:01 a.m. Nov. 10, 2014 - GlobeNewswire
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast 8:16 a.m. Oct. 22, 2014 - GlobeNewswire
OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer 3:01 p.m. Oct. 7, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society 3:02 p.m. Oct. 6, 2014 - GlobeNewswire
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors 3:01 p.m. Sept. 17, 2014 - GlobeNewswire
OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9 3:01 p.m. Aug. 26, 2014 - GlobeNewswire
OXiGENE Reports Second Quarter 2014 Financial Results 3:01 p.m. Aug. 5, 2014 - GlobeNewswire
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 10:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. July 23, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 7:29 a.m. June 20, 2014 - PR Newswire - PRF
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors 7:01 a.m. June 17, 2014 - BusinessWire - BZX
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering 8:01 a.m. May 23, 2014 - GlobeNewswire
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer 7:32 a.m. May 16, 2014 - GlobeNewswire
OXiGENE Reports First Quarter 2014 Financial Results 3:01 p.m. May 6, 2014 - GlobeNewswire
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. April 22, 2014 - GlobeNewswire
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE 7:26 a.m. April 22, 2014 - PR Newswire - PRF
Herbalife tumbles on FTC probe; Plug Power rebounds 3:30 p.m. March 12, 2014 - Sue Chang
Oxigene shares more than double on ovarian cancer treatment results 9:58 a.m. March 12, 2014 - Russ Britt
Stock futures pulled lower by China, Ukraine worries 8:23 a.m. March 12, 2014 - William L. Watts
Plug plunges, Ukraine pops and how Twitter traded the bull market 8:09 a.m. March 12, 2014 - Shawn Langlois
Oxigene shares surge after positive clinical trial 7:39 a.m. March 12, 2014 - Saumya Vaishampayan
VeriFone shares surge after earnings, outlook 4:22 p.m. March 11, 2014 - Wallace Witkowski
Oxigene soars on ovarian cancer drug results 4:05 p.m. March 11, 2014 - MarketWatch.com
Oxigene shares jump 122% to $5.37 on study result 4:00 p.m. March 11, 2014 - Wallace Witkowski
Monday’s biggest gaining and declining stocks 5:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 2:42 p.m. June 6, 2011 - Val Brickates Kennedy
Oxigene soars on Nasdaq update 8:46 a.m. June 6, 2011 - Val Brickates Kennedy
U.S. stock futures drift; Apple’s Jobs ahead 8:04 a.m. June 6, 2011 - Kate Gibson
Diet-drug makers grab sector spotlight 2:53 p.m. June 3, 2011 - Val Brickates Kennedy
Oxigene rallies 30% ahead of study presentations 11:39 a.m. June 3, 2011 - Val Brickates Kennedy
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against? 11:42 a.m. Nov. 17, 2014 - Seeking Alpha
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated 4:20 p.m. Nov. 14, 2014 - Seeking Alpha
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy 9:15 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: OXIGENE INC 10:30 a.m. Nov. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript 9:27 p.m. Nov. 12, 2014 - Seeking Alpha
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast 4:25 p.m. Nov. 12, 2014 - Seeking Alpha
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data 5:12 a.m. Nov. 12, 2014 - TheStreet.com
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact 5:56 a.m. Nov. 11, 2014 - Seeking Alpha
OxiGene presents Phase 2 data on fosbretabulin 12:31 p.m. Nov. 10, 2014 - Seeking Alpha
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting 10:15 a.m. Nov. 6, 2014 - Seeking Alpha
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta 7:28 a.m. Oct. 24, 2014 - TheStreet.com
Update: OXiGENE Initiates Clinical Trial -- Shares Rise 6:35 a.m. Sept. 18, 2014 - Seeking Alpha
Update: OXiGENE Earnings - Q2 Miss Challenges My Patience 11:48 a.m. Aug. 6, 2014 - Seeking Alpha
OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 Results - Earnings Call Transcript 7:29 p.m. Aug. 5, 2014 - Seeking Alpha
OXiGENE (OXGN) Q2 2014 Results - Earnings Call Webcast 3:25 p.m. Aug. 5, 2014 - Seeking Alpha
Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis 2:00 p.m. July 28, 2014 - Seeking Alpha
10-Q: OXIGENE INC 2:44 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE's (OXGN) CEO Peter Langecker on Q1 2014 Results - Earnings Call Transcript 7:21 p.m. May 6, 2014 - Seeking Alpha
Q1 2014 O Xi Gene, Inc Earnings Conference Call (OXGN) Q1 2014 Results - Earnings Call Webcast 3:25 p.m. May 6, 2014 - Seeking Alpha
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting 8:01 a.m. Nov. 20, 2014 - GlobeNewswire
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies 4:01 p.m. Nov. 17, 2014 - GlobeNewswire
OXiGENE Reports Third Quarter 2014 Financial Results 4:04 p.m. Nov. 12, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer 3:01 a.m. Nov. 10, 2014 - GlobeNewswire
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast 8:16 a.m. Oct. 22, 2014 - GlobeNewswire
OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer 3:01 p.m. Oct. 7, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society 3:02 p.m. Oct. 6, 2014 - GlobeNewswire
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors 3:01 p.m. Sept. 17, 2014 - GlobeNewswire
OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9 3:01 p.m. Aug. 26, 2014 - GlobeNewswire
OXiGENE Reports Second Quarter 2014 Financial Results 3:01 p.m. Aug. 5, 2014 - GlobeNewswire
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 10:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. July 23, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 7:29 a.m. June 20, 2014 - PR Newswire - PRF
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors 7:01 a.m. June 17, 2014 - BusinessWire - BZX
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering 8:01 a.m. May 23, 2014 - GlobeNewswire
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer 7:32 a.m. May 16, 2014 - GlobeNewswire
OXiGENE Reports First Quarter 2014 Financial Results 3:01 p.m. May 6, 2014 - GlobeNewswire
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. April 22, 2014 - GlobeNewswire
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE 7:26 a.m. April 22, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼
